Sign in. Results Packs. About us. Fact Sheet. Result in Brief. Objective "Oncologists still rely heavily on biological characterisation of tumours and a limited number of biomarkers which have demonstrated clinical utility.
Routine cancer diagnostic tools may not be always sensitive enough and may only detect proteins at levels corresponding to an advanced stage of the disease. Recently, new genomic and proteomic molecular tools molecular signatures are being employed which include genetic and epigenetic signatures, changes in gene expression, protein profiles and post-translational modification of proteins. Such advanced diagnostic tools are not always readily adapted to clinical cancer screening due to their complexity, costs and the requirement for highly-qualified operators.
A key scientific target is the realisation of intelligent electronic devices which respond to biomolecules such as formaldehyde, amines, metal ions, saccharides, activities of amine oxidases, arginase and glutathione-S-transferase. This will entail design, development and characterisation of nano-scale transducers suitable for testing in clinical samples. Activity type Higher or Secondary Education Establishments. Website Contact the organisation. Administrative Contact Eithne Dempsey Prof.
Status Closed project. Start date 1 January End date 31 December Biosensors for cancer diagnosis Novel bioanalytical methodologies for detection of specific biomarkers are essential for better diagnostics. Current molecular-based assays for routine diagnosis of cancer may lack sensitivity or be suitable only for advanced stages of the disease.
As a result, novel tools that evaluate the molecular profile of tumours at the genetic, epigenetic, transcriptomic and protein level are now being employed. However, their complexity and cost have hampered their routine use in clinical diagnosis so far. The idea was to develop sensitive devices based on nanostructured electronic sensors that are suitable for medical laboratories.
The devices would be able to detect various biomarkers including small molecules, metal ions, enzymes and cancer-related proteins. In the initial part of the project, scientists focused on the immobilisation of bio and nanomaterials on various conducting surfaces. This involved attachment, deposition and cross-linking of a range of innovative materials onto transducers with subsequent optimisation analytical parameters sensitivity, selectivity.
The chemical or enzymatic transformation at the sensor is proportional to the target molecule concentration in the biological sample. The team tested and optimised the sensitivity, specificity, dynamic range of response, reliability and operational stability of the devices. To enhance the sensitivity in electronic sensor output, nanosize recognition membranes were developed. Using the therapeutic drug tamoxifen as a model, researchers evaluated the possibility of therapeutic drug monitoring using mobile phone interfaces for chemosensing.
They also assessed the viability of in situ detection of cancer cells based on selective binding at an aptasensor followed by label-free detection. They have the potential to complement existing time- and labour-consuming clinical tests, considerably expediting sample analysis. Most importantly, they should facilitate accurate diagnosis.
Discover other articles in the same domain of application. The project was based on mutually beneficial research strategies and contributed significantly to integration of related research activity from a wide geographic area. The international and interdisciplinary Consortium of research teams, who came together in order to establish the objectives outlined above are composed of six EU Member States Ireland, Romania, Spain, Portugal, Sweden and France.
Three of these countries Ukraine, Egypt and Tunisia are also listed among the countries covered by the European Neighbourhood Policy ENP and the latter two have become recently associated countries. Transition metal and inorganic species e. Small molecules e. Protein biomarkers e. Tumour circulating cells and miRNA. Such biomarkers of disease are implicated in cancer of the breast, neck, head, thyroid gland, liver, lung, prostate gland, ovary, cervical, pancreatic carcinoma, glyoblastoma and many tumours of neuroectodermal origin etc.
Special attention has been paid to the synthesis and immobilisation of recognition molecules in the presence of redox active nano-objects with the view of creating nano-sized recognition membranes with enhanced sensitivity to the target molecules in question. Archive Journals.
All Journals. New Titles. Pick and Choose. Literature Updates.
Graphene Biosensors to Detect Lung Cancer
Biosensors and biomarkers: promising tools for cancer diagnosis - MedCrave online
This article is part of the themed collection: Electrochemistry for health applications. You have access to this article. Please wait while we load your content Something went wrong. Try again?
- Over 280,000 people receive our email newsletter.
- The Zend Avesta!
- Fluorescence biosensors detect, measure cancer cells' ability to metastasize?
Cited by. Back to tab navigation Download options Please wait Article type: Critical Review. DOI: Download Citation: Anal. Electrochemical biosensors for autoantibodies in autoimmune and cancer diseases S.